Results 121 to 130 of about 862,104 (211)
Some of the next articles are maybe not open access.
Journal of Pharmacology and Experimental Therapeutics, 1994
Systemic administration of dopamine antagonists increases the activity of some dopamine neurons in the substantia nigra, and this effect is thought to occur through two potential mechanisms: 1) local blockade of dopamine acting at somatodendritic ...
M. L. Pucak, A. Grace
semanticscholar +1 more source
Systemic administration of dopamine antagonists increases the activity of some dopamine neurons in the substantia nigra, and this effect is thought to occur through two potential mechanisms: 1) local blockade of dopamine acting at somatodendritic ...
M. L. Pucak, A. Grace
semanticscholar +1 more source
Dopamine antagonists and migraine
Drug Development Research, 2007AbstractMigraine is common impairing disorder resulting from activation of the trigeminovascular system. Evidence suggests that dopaminergic mechanisms are important in migraine, including the premonitory phase. Dopamine antagonists have been used successfully as a primary therapy for migraine in urgent care settings and as adjuvant therapy on an ...
openaire +1 more source
Charged analogs of chlorpromazine as dopamine antagonists
Journal of Medicinal Chemistry, 1987Chlorpromazine (1, CPZ) is a potent dopamine antagonist that has been used widely as an antipsychotic agent. Since dopaminergic antagonists, like dopaminergic agonists, exist in solution as the charged and uncharged molecular species, it is not clear which form of the amine is most important for interaction with the dopamine receptor.
M W, Harrold +6 more
openaire +2 more sources
Dopamine D3 receptor antagonists as therapeutic agents
Drug Discovery Today, 2005The behavioral and pathophysiological role of the dopamine D(3) receptor, which was deduced from anatomical, lesion and drug treatment studies in the ten years following cloning of the receptor, indicated that its functions differed from those of the D(2) receptor.
Jeffrey N, Joyce, Mark J, Millan
openaire +2 more sources
Highlights of D1 dopamine receptor antagonist research
Neurochemistry International, 1992SCH 39166 is now undergoing clinical trials in schizophrenics as a selective D1 dopamine receptor antagonist. It differs from SCH 23390, the prototype D1 receptor antagonist, by having reduced affinity for serotonin receptors and a longer duration of action in primates, as measured in the squirrel monkey conditioned avoidance paradigm.
A, Barnett, R D, McQuade, C, Tedford
openaire +2 more sources
[Dopamine antagonists in anovulation?].
Zentralblatt fur Gynakologie, 1991Increased hypothalamic dopamine turnover may prevent the ovulatory LH peak by different mechanisms and may in this way result in anovulation. Ten patients with anovulatory menstrual cycles who had been treated with clomiphene citrate without success were given the dopaminolytic drug pimozide (Antalon) at a dose of 5 mg/day orally either from day 7 to ...
U, Ulrich +4 more
openaire +1 more source
European Neuropsychopharmacology, 1991
Animal data suggest that a D1 antagonistic component in neuroleptic drugs counteracts development of dopamine supersensitivity and of tolerance to cataleptic effect. This has led to the hypothesis that neuroleptics with D1 antagonistic activity should cause a better suppression of tardive dyskinesia (TD) and less rebound aggravation after withdrawal ...
H, Lublin +7 more
openaire +2 more sources
Animal data suggest that a D1 antagonistic component in neuroleptic drugs counteracts development of dopamine supersensitivity and of tolerance to cataleptic effect. This has led to the hypothesis that neuroleptics with D1 antagonistic activity should cause a better suppression of tardive dyskinesia (TD) and less rebound aggravation after withdrawal ...
H, Lublin +7 more
openaire +2 more sources
Selective Dopamine D1 and D2 Receptor Antagonists
1989The concept of selective dopamine D1 and D2 receptor antagonists is rather new. Previously, dopamine receptor antagonism was evaluated simply as the ability to inhibit dopamine- or dopamine agonist-mediated behaviour or biochemical responses. In 1979 Kebabian and Calne introduced the dopamine D1 and D2 receptor concept based on differential linkage to ...
J, Hyttel, J, Arnt, M, van den Berghe
openaire +2 more sources
Dopamine D3 Receptor Ligands with Antagonist Properties
ChemInform, 2002AbstractFor Abstract see ChemInform Abstract in Full Text.
Anneke E, Hackling, Holger, Stark
openaire +2 more sources
Selective dopamine D4 receptor antagonists
Expert Opinion on Therapeutic Patents, 1998The discovery that the atypical antipsychotic clozapine has higher affinity for the dopamine D4 receptor relative to the D2 receptor touched off a search for more potent, highly selective D4 antagonists as a new class of antipsychotics. Many compounds achieving high potency and selectivity are now available including L-745,870 (Merck), NGD 94-1 ...
openaire +1 more source